Are the IGF-1 and insulin receptors related?

Yes, structurally and evolutionarily, as the name insulin-like growth factor records. Their ligands are related too.

IGF-1 and the Insulin Receptor

The short answer

The IGF-1 receptor and the insulin receptor are structurally related, and cells expressing both can assemble hybrid receptors containing subunits of each. That relatedness means neither ligand is entirely selective for its own receptor.

Key facts

Relationship: Structurally homologous receptors
Hybrids: Contain subunits of both
Consequence: Selectivity is relative, not absolute
Chimeric receptor work: Schäffer 1993 (PMID 8428981)
Journal: J Biol Chem, 15 February 1993
Practical relevance: Glucose handling, oncology targeting

Why the two receptors resemble each other

Insulin and IGF-1 are themselves structurally related, as the name insulin-like growth factor records directly. Both descend from a common ancestral system, and their receptors descend alongside them. Shared ancestry produces shared architecture, and shared architecture produces overlapping ligand recognition.

What a hybrid receptor is

Both receptors assemble from subunit pairs. In a cell expressing both, assembly can mix them, producing a receptor with one half from each. Hybrids have their own binding characteristics, distinct from either parent receptor, and their abundance depends on the relative expression of the two in that cell. The pharmacology therefore becomes cell-type dependent.

Research material referenced

IGF-1 LR3 1mg, third-party HPLC tested

Buy IGF-1 LR3 · £44.99

How the relationships were mapped

By building chimeric receptors and hybrid ligands and testing which combinations bind. Schäffer and colleagues examined interactions of a hybrid insulin and IGF-I analogue with chimeric insulin and type I IGF receptors in the Journal of Biological Chemistry in 1993. Swapping defined regions between two related molecules and observing what changes is how the determinants of selectivity get identified.

Why this matters for glucose

IGF-1 engaging insulin receptors, or hybrids, produces insulin-like metabolic effects. That is a documented property of the system rather than a hypothetical, and it means anything raising free IGF-1 availability has a route to affecting glucose handling that is separate from its growth-related effects.

Why it complicated the oncology programmes

Blocking IGF-1R without touching insulin receptors or hybrids is difficult because of the structural similarity. That is one of the reasons anti-IGF-1R development proved harder than the biology suggested. The target could not be engaged cleanly, and disturbing insulin signalling has immediate consequences.

What follows for an engineered analogue

An analogue designed to increase free IGF-1 increases engagement of whatever that free IGF-1 reaches, which includes insulin receptors and hybrids in proportion to their local abundance. Selectivity is a property of the receptor landscape as much as of the molecule, and it cannot be fully specified from the sequence alone.

Frequently asked questions

Are the IGF-1 and insulin receptors related?: Yes, structurally and evolutionarily, as the name insulin-like growth factor records. Their ligands are related too.
Why does this matter?: It means selectivity is relative. IGF-1 engaging insulin receptors or hybrids produces insulin-like metabolic effects, and it complicated IGF-1R oncology targeting.

Extended research context

The IGF-1 LR3 deep dive

Deep dive: the design that runs backwards from everything else here

Almost every engineered compound in this catalogue solves the same problem in the same direction. Semaglutide attaches a C18 diacid, retatrutide and tirzepatide a C20, all to bind serum albumin and extend duration. CJC-1295's DAC goes further and binds albumin covalently at Cys34. The strategy throughout is to add binding, so the molecule survives longer in circulation. IGF-1 LR3 does the reverse. Its two modifications, arginine replacing glutamate at position 3, and a thirteen-residue N-terminal extension,exist to REMOVE binding, specifically to the IGF binding proteins that sequester the overwhelming majority of circulating IGF-1 in a ternary complex with IGFBP-3 and the acid-labile subunit. Same bound-free equilibrium, engineered in the opposite direction. The reason is that the two families face opposite constraints: an incretin peptide is cleared too fast to be useful, while IGF-1 is held too tightly to be available. Baxter's 1994 review in Hormone Research is the standard account of just how tightly.

Deep dive: a certificate written for the wrong failure mode

This is a recombinant protein, and it fails differently from everything else on this site. A synthetic peptide accumulates deletion sequences, because each coupling is slightly less than complete. At 99% efficiency a 39-mer finishes around 68% full-length, and those impurities differ by one residue's mass and show up in a mass spectrum. Ribosomal synthesis does not fail that way at all; a host cell builds the protein correctly or not at all. What contaminates the product instead is everything else the cell contained: host cell proteins, host DNA, and in bacterial systems endotoxin, which is not a protein, does not appear in a protein purity figure, and needs its own assay entirely. Layered on top is a failure mode with no peptide equivalent. This protein has three disulfide bonds, meaning six cysteines that can pair fifteen ways of which one is correct, and Milner and colleagues showed in the Biochemical Journal in 1995 that B-domain mutations influence oxidative folding, which is directly relevant since position 3 sits in the B-domain. A misfolded isomer has identical mass, identical composition, and is invisible to mass spectrometry. A certificate reading exactly like a synthetic peptide's is testing for problems this production route does not have while missing the ones it does.

Deep dive: an approved relative, and why that raises the risk rather than lowering it

Unusually for this catalogue, a licensed IGF-1 medicine exists. Mecasermin, marketed as Increlex, is recombinant human IGF-1 with an FDA label and a subcutaneous route, used in severe primary IGF-1 deficiency. Petriczko and colleagues reported on it in 2019 and Denaite and colleagues in Frontiers in Pediatrics in 2024. That is a real approval with real clinical evidence. It covers the native seventy-residue hormone. LR3 is an eighty-three-residue engineered analogue whose defining feature is deliberately altered binding behaviour, holds no marketing authorisation anywhere, and has no primary literature under its own name. Searches for IGF-1 LR3 and Long R3 IGF-1 return nothing. A nearby approval invites the inference that the analogue is somehow covered by it, and that inference is the most consequential error available in this category. Separately and unconditionally: IGF-1 and its analogues sit in WADA class S2, prohibited at all times, with the list extending to related substances and mimetics so that structural modification creates no exemption.

Research applications

▸Cell culture supplementation where secreted IGFBPs confound dosing
▸IGF binding protein interaction and affinity studies
▸Recombinant protein expression and purification methodology
▸Disulfide folding and oxidative refolding research
▸Comparative work on engineered versus native growth factors
▸Anti-doping analytical method development

Handling checklist

✓Expect no PubChem record. Proteins are indexed in UniProt (native IGF-1 is P05019)
✓Read the certificate for host cell protein, host DNA and endotoxin, not deletion sequences
✓Understand that mass spectrometry cannot detect a misfolded disulfide isomer
✓Treat loss of fold as the principal failure mode. It leaves mass unchanged
✓Avoid shaking and foaming; interfaces unfold proteins and aggregation is irreversible
✓Use low-binding consumables; adsorption is significant at microgram quantities
✓Aliquot before freezing. Freeze-thaw is worse for a folded protein than a short peptide

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Reading mecasermin's approval as covering IGF-1 LR3

Fix: Increlex is native 70-residue rhIGF-1. LR3 is an 83-residue engineered analogue with altered binding, unlicensed everywhere. The approval does not transfer.

✗ Expecting a synthetic-peptide certificate for a recombinant protein

Fix: There are no deletion sequences here. The relevant tests are host cell protein, host DNA, endotoxin and something addressing conformation.

✗ Treating a clean mass spectrum as proof the protein is intact

Fix: A misfolded disulfide isomer has identical mass and composition. Only an activity or conformational assay addresses folding.

✗ Assuming absence from PubChem is a red flag

Fix: It is expected for a protein of this size. PubChem indexes small molecules, UniProt indexes proteins. This is unlike retatrutide, where absence is odd.

✗ Reading the cell-culture rationale as transferable

Fix: Bypassing IGFBP regulation is useful in a dish, where it is an experimental nuisance. In an organism the same system regulates a growth factor acting on nearly every tissue.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this content Report a factual error in this article

Popular across the research hub

One flagship guide from every other research category.

← Back to Forum

Two Receptors Close Enough to Form Hybrids